Arrowhead Pharmaceuticals Reports $264M Revenue Growth and Positive Net Income in Latest Quarter

Arrowhead Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly filing, with revenues soaring to $264.0 million for the three months ended December 31, 2025, compared to just $2.5 million during the same period in 2024. This remarkable increase is primarily attributed to revenue generated from collaboration agreements with Sarepta Therapeutics and Novartis, which contributed $229.5 million and $34.2 million, respectively. The company also achieved an operating income of $40.8 million, a stark contrast to the operating loss of $161.4 million reported in the previous year.

The company’s total assets increased to $1.6 billion as of December 31, 2025, up from $1.4 billion at the end of the previous quarter. This growth was driven by a rise in current assets, particularly accounts receivable, which surged to $218.9 million from $6.8 million, reflecting the successful execution of its collaboration agreements. Arrowhead's cash, cash equivalents, and restricted cash decreased to $71.4 million, down from $88.7 million, while available-for-sale securities rose to $715.0 million, indicating a strong investment position.

Strategically, Arrowhead has made significant advancements in its product pipeline and collaborations. The FDA approved its drug REDEMPLO for treating Familial Chylomicronemia Syndrome, and the company received a $200 million milestone payment from Sarepta for its ARO-DM1 program. Additionally, Arrowhead initiated a Phase 1/2a clinical trial for ARO-MAPT, targeting Alzheimer’s disease, and filed for regulatory clearance for ARO-DIMER-PA, which aims to treat atherosclerotic cardiovascular disease. The company also entered a global licensing agreement with Novartis, which is expected to yield up to $2 billion in milestone payments and royalties.

Operationally, Arrowhead's employee headcount has expanded as the company prepares for commercialization and further clinical trials. The increase in research and development expenses, which rose to $177.2 million from $137.0 million year-over-year, reflects the company's commitment to advancing its pipeline. The company reported a net income of $30.8 million, or $0.22 per diluted share, compared to a net loss of $173.1 million, or $(1.39) per diluted share, in the prior year, indicating a positive shift in profitability.

Looking ahead, Arrowhead anticipates continued growth driven by its expanding pipeline and strategic collaborations. The company expects to maintain sufficient liquidity to fund operations through at least the next twelve months, bolstered by its recent capital raises and collaboration agreements. The outlook remains optimistic as Arrowhead continues to innovate in RNAi therapeutics, aiming to address significant unmet medical needs.